Editas Medicine to Present at the 37th Annual J.P. Morgan Healthcare Conference
02. Januar 2019 08:30 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present a company overview followed by a...
Editas Medicine Announces Third Quarter 2018 Results and Update
07. November 2018 16:01 ET
|
Editas Medicine, Inc.
Filed IND application for EDIT-101 with FDA in October Favorable Appeals Court ruling affirms strength of foundational intellectual property Oral presentation at ASH Annual Meeting to highlight...
Editas Medicine to Host Conference Call Discussing Third Quarter 2018 Corporate Update and Results
31. Oktober 2018 16:01 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on...
Editas Medicine Announces Second Quarter 2018 Results and Update
06. August 2018 16:05 ET
|
Editas Medicine, Inc.
Allergan exercises option to develop and commercialize EDIT-101 globally and Editas exercises option to co-develop and equally share profits and losses in the United States Plan to file EDIT-101...